Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04484220 · ClinicalTrials.gov registry record · NA
Ellipsys Vascular Access System Post Market Surveillance (PS) Study
A NA study, sponsored by Medtronic Endovascular.
- Completed
- Registry status
- NA
- Development phase
- 142
- Enrollment target
NCT04484220: Completed NA study, sponsored by Medtronic Endovascular.
NCT04484220 is a NA study that has completed, run by Medtronic Endovascular. The registered enrollment target is 142 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04484220, a NA study, has completed, sponsored by Medtronic Endovascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 142 participants
- Enrollment target
Study Summary
The proposed clinical study is a prospective, non-randomized, multi-center, single-arm, observational, post-market surveillance (PS) study of the Ellipsys Vascular Access System in subjects eligible for arteriovenous (AV) fistula.
Primary Outcome
Freedom from access abandonment from time of access creation
Interventions
- DEVICE Ellipsys Vascular Access System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2021-04-13 |
| Est. Completion | 2025-03-31 |
| Phase | NA |
What the finished NCT04484220 record still lists
NCT04484220 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Ellipsys Vascular Access System is the first listed.
NCT04484220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04484220 about?
NCT04484220 is a clinical study titled "Ellipsys Vascular Access System Post Market Surveillance (PS) Study". The proposed clinical study is a prospective, non-randomized, multi-center, single-arm, observational, post-market surveillance (PS) study of the Ellipsys Vascular Access System in subjects eligible for arteriovenous (AV) fistula.
What is the current status of trial NCT04484220?
This trial is currently completed. It is a NA study. The enrollment target is 142 participants. The study started on 2021-04-13. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT04484220?
The interventions under investigation include: Ellipsys Vascular Access System (DEVICE).
Who is sponsoring clinical trial NCT04484220?
This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04484220's enrollment target sits among peer trials
142 711th of 2000 higher than 1,289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI